Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

NervGen Pharma Yönetim

Yönetim kriter kontrolleri 1/4

NervGen Pharma's CEO'su Mike Kelly, Apr2023 tarihinde atandı, in görev süresi 1.5 yıldır. in toplam yıllık tazminatı CA$ 740.33K olup, şirket hissesi ve opsiyonları dahil olmak üzere 72.9% maaş ve 27.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.21% ine doğrudan sahiptir ve bu hisseler CA$ 369.96K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.5 yıl ve 3.8 yıldır.

Anahtar bilgiler

Mike Kelly

İcra Kurulu Başkanı

CA$740.3k

Toplam tazminat

CEO maaş yüzdesi	72.9%
CEO görev süresi	1.5yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	1.5yrs
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

We're Interested To See How NervGen Pharma (CVE:NGEN) Uses Its Cash Hoard To Grow

Jun 11

NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 31% Below Their Intrinsic Value Estimate

Feb 02

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Nov 23

We Think NervGen Pharma (CVE:NGEN) Needs To Drive Business Growth Carefully

Jun 29

We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Mar 16

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Mar 08

CEO Tazminat Analizi

Mike Kelly'un ücretlendirmesi NervGen Pharma'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-CA$23m
Mar 31 2024	n/a	n/a	-CA$20m
Dec 31 2023	CA$740k	CA$540k	-CA$22m

Tazminat ve Piyasa: Mike 'nin toplam tazminatı ($USD 548.73K ), Canadian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 177.89K ).

Tazminat ve Kazançlar: Mike şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Mike Kelly (58 yo)

1.5yrs

Görev süresi

CA$740,330

Tazminat

Mr. Michael Kelly, also known as Mike, is an Independent Director of ARS Pharmaceuticals, Inc. and joined in May 2019. He serves as Chief Executive Officer, President and Director of NervGen Pharma Corp. s...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Kelly	CEO, President & Director	1.5yrs	CA$740.33k	0.21% CA$ 348.4k
William Radvak	Co-Founder & Advisor	no data	CA$60.00k	0% CA$ 0
Harold Punnett	Co-Founder & Independent Director	no data	Veri yok	1.6% CA$ 2.7m
William Adams	CFO & Corporate Secretary	4.7yrs	CA$431.63k	0.22% CA$ 377.1k
Daniel Mikol	Chief Medical Officer	3.4yrs	CA$793.99k	Veri yok
Brian McAlister	Co-Founder & Advisor	no data	Veri yok	Veri yok
Charles Olson	Senior Vice President of Technical Operations	less than a year	Veri yok	Veri yok
Elizabeth Eberhardt	Senior Vice President of Program Management	less than a year	Veri yok	Veri yok

1.5yrs

Ortalama Görev Süresi

61.5yo

Ortalama Yaş

Deneyimli Yönetim: NGEN 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.5 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Kelly	CEO, President & Director	1.5yrs	CA$740.33k	0.21% CA$ 348.4k
Harold Punnett	Co-Founder & Independent Director	7.8yrs	Veri yok	1.6% CA$ 2.7m
Brian McAlister	Co-Founder & Advisor	no data	Veri yok	Veri yok
Glenn Ives	Chairman	3.1yrs	Veri yok	0.083% CA$ 141.6k
Brian Bayley	Independent Director	6.4yrs	Veri yok	0.57% CA$ 968.0k
Randall Kaye	Independent Director	4yrs	Veri yok	0.014% CA$ 24.2k
Jeffrey Cummings	Member of Alzheimer's Disease Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
Jerry Silver	Co-Inventor & Scientific Advisor	no data	Veri yok	Veri yok
George Perry	Member of Alzheimer's Disease Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
Henrik Zetterberg	Member of Alzheimer's Disease Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
Michael Davis	Advisor	4yrs	Veri yok	Veri yok
Bruce Lamb	Member of Alzheimer's Disease Scientific Advisory Board	3.8yrs	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

66.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NGEN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

NervGen Pharma Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

NervGen Pharma Corp. Appoints Neil Klompas to Board of Directors

Insufficient new directors

NervGen Pharma Corp. Approves Board and Audit Committee Elections

CEO, President & Director recently bought CA$338k worth of stock

NervGen Pharma Corp., Annual General Meeting, Jun 04, 2024

Recent updates

Insufficient new directors

NervGen Pharma Corp. Appoints Neil Klompas to Board of Directors

We're Interested To See How NervGen Pharma (CVE:NGEN) Uses Its Cash Hoard To Grow

Insufficient new directors

NervGen Pharma Corp. Approves Board and Audit Committee Elections

New minor risk - Market cap size

New major risk - Negative shareholders equity

CEO, President & Director recently bought CA$338k worth of stock

NervGen Pharma Corp., Annual General Meeting, Jun 04, 2024

New minor risk - Market cap size

Independent Director exercised options to buy CA$272k worth of stock.

Co-Founder & Independent Director exercised options to buy CA$347k worth of stock.

New minor risk - Share price stability

Is NervGen Pharma (CVE:NGEN) In A Good Position To Invest In Growth?

NervGen Pharma Corp. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury

Nervgen Pharma Appoints John Ruffolo to Board of Directors

NervGen Pharma Corp. Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury

Here's Why We're Watching NervGen Pharma's (CVE:NGEN) Cash Burn Situation

Price target increased by 8.6% to CA$6.00

Will NervGen Pharma (CVE:NGEN) Spend Its Cash Wisely?

NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291

NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 31% Below Their Intrinsic Value Estimate

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

High number of new and inexperienced directors

Nervgen Pharma Corp. Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291

NervGen Pharma Corp. Receives Up to $1.5 Million US Department of Defense Funding to Evaluate NervGen's NVG-291-R for Peripheral Nerve Injury

NervGen Pharma Corp. Announces Executive Changes

NervGen Pharma Corp., Annual General Meeting, Sep 28, 2022

NervGen Pharma Corp. announced that it has received $15.225 million in funding from PFP Biosciences Holdings

NervGen Pharma Corp. Appoints Adam Rogers to its Board of Directors

NervGen Pharma Corp. announced that it expects to receive $15.225 million in funding

We Think NervGen Pharma (CVE:NGEN) Needs To Drive Business Growth Carefully

Nervgen Pharma Corp. Receives Approval from the Safety Review Committee to Advance to the Third and Highest Dose Cohort in the Multiple Ascending Dose Portion of Phase 1 Clinical Trial of the Company's Proprietary Lead Compound, NVG-291

President exercised options to buy CA$112k worth of stock.

Independent Director exercised options to buy CA$224k worth of stock.

Less than half of directors are independent

NervGen Pharma Corp. Announces Executive Changes

We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

High number of new directors

NervGen Pharma Corp. announced that it has received CAD 2.321075 million in funding

NervGen Pharma Corp. announced that it has received CAD 2.343036 million in funding

NervGen Pharma Corp. has completed a Composite Units Offering in the amount of CAD 5.0375 million.

NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-291

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

NervGen Pharma Corp. Provides Regulatory Update on Development Program for NVG-291

Nervgen Pharma Adds Alzheimer's Disease Patient Cohort to Its Phase 1 Clinical Trial Program

New 90-day high: CA$2.41

New 90-day high: CA$1.90

New 90-day high: CA$1.85

NervGen Pharma Corp. Appoints Dr. Randall Kaye to the Company's Board of Directors

NervGen Pharma Corp. Provides an Update on NVG-291

New 90-day low: CA$1.43

New 90-day low - CA$1.52

NervGen Pharma Corp. has completed a Composite Units Offering in the amount of CAD 6.45 million.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş